Oncology

Champions Oncology will be presenting data on it's preclinical model at the ongoing EORTC-NCI-AACR Symposium in Barcelona. The model proposes to help develop individualized treatments for patients.

Scientists at the Memorial Sloan Kettering Cancer Center have identified that tumor mutation burden could help predict responders to ipilimumab treatment. The report has been published online in the New England Journal of Medicine.

A recent study published in European Urology highlights quality-of-life benefits with active surveillance in men with prostate cancer.

Vermont Senator Bernie Sanders has introduced a bill that would require generic drugmakers to pay rebates to the federal Medicare and Medicaid programs when prices of their medications outpace inflation.

The study, published in Cell Reports, evaluates the dynamic protein interactions that promote different diseases including cancer. By capturing these interactions, the authors hope to discover new drug targets.

The retrospective study, published in JAMA Surgery, could not necessarily point to the underlying reason for this treatment choice.

According to the report, sofosbuvir for hepatitis C infections and new cancer drugs were the drivers of the high spending costs, a 7% jump over the previous year.

After 4 years of living with inflammatory breast cancer, Amy Berman, RN, BS, senior program officer at the John A. Hartford Foundation, she still felt fine, which she attributed to her care choices, she explained during her speech at The American Journal of Managed Care's Patient-Centered Oncology Care meeting in Baltimore, Maryland.

The study, published in the Journal of Thoracic Oncology, identified race, insurance status, and the treatment center as variables that influenced treatment received by individuals with early-stage lung cancer.

In a paper published in the Journal of Clinical Oncology, medical oncologists have delineated their recommendations to improve cancer care and provide better access to quality care for those patients with financial issues and on Medicaid.

The evolving field of precision medicine is very much reliant on diagnostics, Howard K. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, said at The American Journal of Managed Care's Patient-Centered Oncology Care meeting.

An electrical device glued to the scalp can slow cancer growth and prolong survival in people with the deadliest type of brain tumor, researchers reported on Saturday in Miami, at a meeting of the Society for Neuro-Oncology.

The collaboration between the 2 drug giants will prove a big boost to Merck's cancer immunotherapy MSB0010718C, and will also improve it's global oncology business.

At its third annual conference, Patient-Centered Oncology Care 2014, The American Journal of Managed Care addressed new challenges in cancer care: more patients have coverage, but they may be "underinsured" or barred from academic centers. Amid rising drug costs and regulations that threaten community practices, the head of the largest oncology organization outlined a path toward value-based reimbursement.

In a press release based off-of results presented at the Society for Melanoma Research 2014 International Congress in Zurich, Switzerland, BMS announced results from phase 3 of the CheckMate-066 trial.

Following encouraging results from a second phase of a phase 1 trial, the researchers have planned a second phase, to be initiated in January 2015. The vaccine will be administered to glioblastoma patients just before they begin chemotherapy.